2026-10-25
Masimo clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,465 −1.17%
S&P 7,723 −0.27%
GOLD $4,035 −0.40%
BTC $81,733 +0.57%
VIX 16.46 −2.66%
latest tape · as of 16:04 UTC
The Screen · Healthcare · Medical Devices
Masimo Corporation
MASI · Nasdaq · USD · Market cap $9.4B · 2,200 employees
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
Not yet scored179.95 USD
Price as of 6 Aug 2026Daily close, not a live quoteLast reviewed 84 days ago
Screened 2026-08-06 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price179.95 USD at the 6 Aug 2026 close
- Our ratingQuality, fully valued, current read accumulation
- Ethical screenNot yet scored
- Last reviewed6 Aug 2026 (84 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 179.95 against the desk's fair-value range, base estimate 163.75, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price179.95 USD
Fair value163.75
Ethical score97.5/100
RatingQUALITY, FULLY VALUED
Our investment reviews on this name
2026-07-02Read Accumulation178.82+0.6% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Masimo Corporation holds its Accumulation at $179.95. Consolidating, no directional conviction, held for 18 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 18 days |
| Price at the screen | $179.95 |
| Valuation | 44.43 trailing · 26.84 forward price to earnings |
| Values screen | Not scored · score 97.5 |
| Beta | 1.10 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 5.20% | Below 33% | Interest-bearing debt is just 5.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 1.33% | Below 33% | Cash held in interest-bearing accounts and securities is 1.3% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Masimo clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Masimo clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 5%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads QUALITY, FULLY VALUED: it trades above our $163.75 fair value estimate, moderate competitive moat, 8.50% revenue growth.
Fair value range in USD, drawn from the 2026-08-06 screen. The gold marker is the market price at the same screen. The price runs 9.0% above the base estimate.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPulse oximeters priced beyond their signals
Picture a nurse trusting a clip on a finger during chaos, only to learn the company behind it wants investors to pay top dollar for steady but unspectacular growth. Masimo clears the ethical screen yet trades at a 26.9 times forward multiple on 8 percent revenue growth and a thin 5 percent profit margin. Fair value sits 9 percent below the current price, leaving no margin of safety despite a moderate moat and solid 25 percent ROE.
We pass because the numbers do not support the premium. Analysts sit on a hold rating with a median target near the present quote, which tells us the market already prices in most of the visible runway. A business this size rarely compounds fast enough to justify stretching the multiple further.
The real risk lies in competition chipping away at that moat while healthcare budgets stay tight. Low margins leave little room for error if growth slows or reimbursement changes hit. Analysis, not advice.
| Forward P/E | 26.8xexpensive even after accounting for its growth |
| Trailing P/E | 44.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 4.05 |
| EPS, forward | 6.71 |
| Revenue growth | +8.5%steady growth |
| Profit margin | 4.9%barely profitable |
| Return on equity | 25.0%an exceptional return on shareholder capital |
| FCF yield | 3.48% |
| Debt to equity | 0.62moderate, manageable leverage |
| Current ratio | 2.68comfortably covers its short-term bills |
| Beta | 1.10moves a little more than the market |
| Short interest, float | 0.07% |
| 52-week range | 125.94 - 179.99 |
| Moat | MODERATE |
| Market cap | $9.4B |
| Employees | 2,200 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Titan Case StudyOur full written analysis of MASI: MASI Case Study → 2026-07-02
Where & How to TradeMASI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-20
Accumulation $179.95
+0.0% Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-10-02
Accumulation $179.95
+0.0% Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-09-04
Accumulation $179.95
+0.0% Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-08-05
Accumulation $179.95
+0.6% Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-07-18
Accumulation $178.82
+0.0% Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (4 analysts) rates it none, with a mean price target of $180.
2026-07-03
Accumulation $178.82
+0.0% Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (98). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
Accumulation $178.82
Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with near-perfect ethical score (98). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Masimo (MASI) Gains FDA Pediatric Clearance, But Is The Valuation Already Priced In? Simply Wall St. · 3 Aug 2026
- Should Masimo’s Radius VSM Safety Recalls Prompt a Reassessment From Masimo (MASI) Investors? Simply Wall St. · 24 Jul 2026
- Masimo (MASI) Following Recall News Why The Stock Still Looks Fairly Valued Simply Wall St. · 20 Jul 2026
- Danaher Boosts Product Portfolio With the Acquisition of Masimo Zacks · 12 Jun 2026
- Danaher Closes Acquisition of Masimo; Maintains Q2, 2026 Outlook MT Newswires · 10 Jun 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
BIOBio-Rad Laboratories, Inc.
PODDInsulet Corporation
GKOSGlaukos Corporation
BRKRBruker Corporation
GMEDGlobus Medical Inc
SNNSmith & Nephew plc ADR
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-29 | LANE WENDY E. | Director | 1,225 | · | |
| 2026-04-29 | BRENNAN MICHELLE | Chairman of the Board | 1,225 | · | |
| 2026-04-29 | SCANNELL TIMOTHY J. | Director | 1,225 | · | |
| 2026-04-21 | HELLMANN ELISABETH A | Officer | 335 | · | |
| 2026-03-11 | SZYMAN CATHERINE M | Chief Executive Officer | 2,101 | · | |
| 2026-03-11 | YOUNG MICAH W | Chief Financial Officer | 873 | · | |
| 2026-02-27 | YOUNG MICAH W | Chief Financial Officer | 15,000 | $2,630,250 | |
| 2026-02-27 | YOUNG MICAH W | Chief Financial Officer | 15,000 | · | |
| 2026-02-26 | YOUNG MICAH W | Chief Financial Officer | 2,034 | · | |
| 2026-02-12 | SZYMAN CATHERINE M | Chief Executive Officer | 11,141 | $1,481,307 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $178.31 | +0.9% | · | $1,009 | +0.9% |
| 2 months | $178.32 | +0.9% | · | $1,009 | +0.9% |
| 3 months | $175.47 | +2.6% | · | $1,026 | +2.6% |
| 6 months | $139.77 | +28.8% | · | $1,288 | +28.8% |
| 1 year | $171.88 | +4.7% | · | $1,047 | +4.7% |
| 2 years | $125.46 | +43.4% | · | $1,434 | +43.4% |
| 3 years | $156.34 | +15.1% | · | $1,151 | +15.1% |
| 5 years | $218.63 | -17.7% | · | $823 | -17.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MASI does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.